Esquire 3000 plus system

All reagents and solvents were purchased from either Sigma-Aldrich (Milwaukee, WI) or Fisher Scientific (Pittsburgh, PA). ¹H NMR spectra were recorded on a Bruker Ultrashield 400 or 500 MHz spectrometer. ESI mass spectra were obtained on a Bruker Esquire 3000 plus system. High-resolution mass spectrometry (HR-MS) was done by the Mass Spectrometry Facility at the University of Notre Dame using ESI by direct infusion on a Bruker micrOTOF-II. High performance liquid chromatography (HPLC) purification was performed on a Varian Prostar System. [¹⁸F]Fluoride was produced by 18 MeV proton bombardment of a high pressure [¹⁸O]H₂O target using a General Electric PET trace biomedical cyclotron (Milwaukee, WI). [¹⁸F]DCFPyL was prepared as previously published.^{14 (link)} Reverse phase radio-HPLC purification was performed using a Varian Prostar System with a Bioscan Flow Count PMT radioactivity detector (Varian Medical Systems, Washington, DC). Radioactivity was measured in a Capintec CRC-10R dose calibrator (Ramsey, NJ). The specific radioactivity was calculated as the radioactivity eluting at the retention time of the product during the semipreparative HPLC purification divided by the mass (determined from a standard curve) corresponding to the area under the curve of the UV absorption.

Reagents and solvents were purchased from either Sigma-Aldrich (Milwaukee, WI) or Fisher Scientific (Pittsburgh, PA). The trifluoroacetate salt of 2-(3-{5-[7-(5-amino-1-carboxy-pentylcarbamoyl)-heptanoylamino]-1-carboxy-pentyl}-ureido)-pentanedioic acid 1 [22 (link)] (Figure 1) was prepared according to our published procedure. IRDye700DX NHS ester was purchased from LI-COR Biosciences (Lincoln, NE). ESI mass spectra were obtained on a Bruker Esquire 3000 plus system. Purification by high performance liquid chromatography (HPLC) was performed on a Varian Prostar System (Palo Alto, CA).